The effect of proteasome inhibition with bortezomib(Velcade™) in B cell lymphoma cell lines

被引：0
|
作者：
Strauss, SJ
Liu, W
Maharaj, L
Shringarpure, R
Anderson, C
Schenkein, D
Lister, TA
Joel, SP
机构：
[1] St Bartholomews Hosp, Dept Med Oncol, London, England
[2] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[3] Millennium Pharmaceut, Boston, MA USA
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S65 / S65
页数：1
相关论文
共 50 条
  • [1] The effect of proteasome inhibitor with Bortezomib (Velcade™) in B-cell lymphoma cell lines
    Strauss, SJ
    Lui, W
    Schenkein, D
    Shringarpure, R
    Anderson, K
    Lister, TA
    Joel, SP
    [J]. BLOOD, 2003, 102 (11) : 903A - 903A
  • [2] Velcade - Bortezomib for injection - MILLENNIUM - Proteasome Inhibitor approved for treatment of relapsed mantle cell lymphoma
    不详
    [J]. FORMULARY, 2007, 42 (01) : 11 - 12
  • [3] Proteasome inhibitor bortezomib (Velcade™) and trastuzumab in HER-2 overexpressing breast cancer cell lines
    Laes, JF
    Cardoso, F
    Durbecq, V
    Lagneaux, L
    Hennuy, B
    Lallemand, F
    Gonze, I
    Di Leo, A
    Kern, F
    Ross, J
    Piccart, MJ
    Sotiriou, C
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S89 - S89
  • [4] Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
    Ying Wang
    Arun K. Rishi
    Vineshkumar T. Puliyappadamba
    Sunita Sharma
    Huanjie Yang
    Adi Tarca
    Q. Ping Dou
    Fulvio Lonardo
    John C. Ruckdeschel
    Harvey I. Pass
    Anil Wali
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 66 : 455 - 466
  • [5] Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
    Wang, Ying
    Rishi, Arun K.
    Puliyappadamba, Vineshkumar T.
    Sharma, Sunita
    Yang, Huanjie
    Tarca, Adi
    Dou, Q. Ping
    Lonardo, Fulvio
    Ruckdeschel, John C.
    Pass, Harvey I.
    Wali, Anil
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 455 - 466
  • [6] Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
    Serra Kamer
    Qing Ren
    Adam P. Dicker
    [J]. Archives of Gynecology and Obstetrics, 2009, 279 : 41 - 46
  • [7] Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
    Kamer, Serra
    Ren, Qing
    Dicker, Adam P.
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2009, 279 (01) : 41 - 46
  • [8] Promising activity of the proteasome inhibitor bortezomib (velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    O'Connor, O
    Wright, J
    Moskowitz, CH
    Muzzy, J
    MacGregor-Cortelli, B
    Hamlin, P
    Straus, D
    Trehu, E
    Schenkein, DP
    Zelenetz, AD
    [J]. BLOOD, 2003, 102 (11) : 636A - 636A
  • [9] Report of a phase II study of proteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory T-cell lymphoma.
    Zinzani, PL
    Tani, M
    Stefoni, V
    Alinari, L
    Marchi, E
    Fina, M
    Baccarani, M
    [J]. BLOOD, 2005, 106 (11) : 271B - 271B
  • [10] Cell cycle Dysregulation represents an early effect of the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Hutter, G
    Zimmermann, Y
    Rieken, M
    Weinkauf, M
    Weigert, O
    Hiddemann, W
    Dreyling, MH
    [J]. BLOOD, 2004, 104 (11) : 629A - 629A
12345